ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer
Melanoma Case Studies

Boris C. Bastian, MD, PhD: BioMerieux and Other Tests in Melanoma

Boris C. Bastian, MD, PhD
Published Online:Aug 03, 2016
Michelle is a 55-year old who was referred by her primary care physician to receive a biopsy for a suspicious mole during a routine visit. Results of the biopsy and other subsequent tests revealed that she had an M1b stage tumor (lung metastasis and a less than ULN LDH level). Her ECOG PS is 0.

Metastatic Melanoma with Adil Daud, MD and Boris C. Bastian, MD, PhD



Which test do you prefer? Is the bioMérieux test preferred, since it detects V600E and K more exclusively?

The bioMerieux test is definitely a step forward in that it basically decreases the number of false negatives. But it’s still missing all the other variants that we discussed earlier—V600 mutations that are not E or K or mutations immediately nearby.

For that reason, we either use Sanger sequencing of exon 15 or we actually more and more use large panel sequencing. We would interrogate all these genes that I just mentioned to really get a comprehensive picture up front rather than using a lot of very focused tests.

CASE: Metastatic Melanoma

Michelle is a 55-year old who was referred by her primary care physician to receive a biopsy for a suspicious mole during a routine visit. Results of the biopsy and other subsequent tests revealed that she had an M1b stage tumor (lung metastasis and a less than ULN LDH level). Her ECOG PS is 0.

  • Initial BRAF testing using a laboratory-developed test was negative for BRAF V600E L
  •  She was referred from the community setting to a tertiary center, at which point a second test was conducted using the bioMérieux HxID-BRAF kit. This assay was positive for the BRAF V600K mutation
  • Following the finding of BRAF-positivity, Michelle was prescribed the combination of dabrafenib (150 mg BID) and trametinib (1 mg daily)
Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.